B acquisition to deliver end-to-end data platform for businesses to connect, process and govern data for applications and AI ...
Coherus Oncology, Inc. (NASDAQ: CHRS) today announced compelling six-year overall survival (OS) follow-up results from the Phase 3 JUPITER-02 trial evaluating LOQTORZI® (toripalimab-tpzi) plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback